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4Abstract
Background: Norwegian guidelines recommend treatment with bisphosphonates for women 
considered at high risk of osteoporosis. Alendronate is the most used bisphosphonate. 
Recently the price of alendronate has fallen by 75% due to the expiring of the patent. This 
may influence the cost effectiveness of the drug.
Objective: To estimate the incremental costs and effects of treating postmenopausal, 
osteopenic women with alendronate in addition to calcium and vitamin D instead of calcium 
and vitamin D alone.
Design: Markov model with seven health states: well, well after fracture, mild hip fracture 
sequela, moderate hip fracture sequela, severe hip fracture sequela, vertebral sequela and 
dead. The model encompasses three events: hip, vertebral and forearm fracture.
Data sources: Literature searches in the databases Medline, EMBASE and Cochrane to 
identify data on fracture incidence, efficacy, of alendronate and quality of life. Costs are 
estimated using Norwegian fee schedules for 2006. Mortality rates for 2006 from Statistics 
Norway.
Target population: Postmenopausal women, aged 65-75 with femoral neck T-score 
between -1.5 and -2.5 living in Oslo. 
Time horizon: Until death or age of 100.
Perspective: Broad health care 
Interventions: Four years of treatment with alendronate. Offset time three years.
Outcome measures: The results are expressed as incremental costs, incremental quality 
adjusted life years, and costs per QALY gained. 
Results: Treatment with alendronate was cost saving and more effective for all groups.
Results of sensitivity analysis: The results of the one-way sensitivity analyses indicate that 
this conclusion is robust to any realistic change of the model input.
Limitations: Results apply mainly to postmenopausal, Caucasian women in Oslo. 
Conclusions: The results indicate that treatment with alendronate, at the current price level,
is cost saving and more effective compared to no treatment for a wide group of women.
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71. Introduction
1.1 Osteoporosis
Osteoporosis is an asymptomatic but still clinically important condition because of its 
association with fractures, particularly fractures in hip, forearm and spine. It is characterised 
by low bone marrow density (BMD), which is a measure of bone strength. 
Bone strength encompasses both bone quantity and quality. It depends on peak bone mass at 
early adulthood and subsequent rate of bone loss. Peak bone mass is determined by heredity, 
sex, dietary factors, endocrine factors, mechanical forces and exposure to risk factors. Bone 
loss accelerates after the menopause, but may also result from age-related conditions such as 
reduced calcium absorption. Certain drugs and medical conditions can produce so-called 
secondary osteoporosis [35].
The balance between bone resorption and bone deposition, and thus whether bone is made, 
maintained or lost, is determined by the activities of two cell types, the osteoblasts who are 
responsible of bone synthesis and subsequent mineralisation, and the osteoclasts that 
function in resorption of mineralized tissue. These mechanisms are not yet fully understood 
[36]. 
Figure 1; Osteoblasts and Osteoclasts [98]
Both men and women, and all age groups are at risk of osteoporosis, but it is most common 
in postmenopausal women. Approximately 30% of all postmenopausal women in Europe 
have osteoporosis [35]. There are few studies on incidence of osteoporosis in Norway, but in 
1998 it was estimated that 14-36% of women above 50 years, living in Oslo, had 
8osteoporosis. Extrapolated to the Norwegian population, this corresponds to 96 000-255 000 
women with osteoporosis [24]. 
Both the incidence and the financial and health related costs of osteoporosis will increase in 
the future as life expectancy, and thus the number of elderly individuals, is increasing [35]. 
1.2 Definition of T-score and Z-score
BMD is often expressed by T-score, which is the number of standard deviations (SD) above 
or below the mean BMD values for a young healthy adult. 
Figure 2; Osteoporosis and Osteopenia, [98]:
Four general diagnostic categories for women, based on BMD values, have been proposed by 
a WHO Study Group [98]:
 Normal BMD: T-score above or equal to -1
 Osteopenia: T-score below -1 and above -2.5
 Osteoporosis: T-score above or equal to -2.5
9 Established osteoporosis: T-score below or equal to -2.5 in addition to one or more 
fragility fractures.
Another measure is Z-score, which is the number of standard deviations above or below the 
mean BMD values for a population of the same age and gender [35]. Figure 3 shows how 
BMD varies with age
Figure 3; BMD and Age [98]:
Table 1 shows the relationship between T-score and Z-score. The table was calculated for us 
by Jan Falch MD based on a reference material from Oslo [23]. 
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Table 1; Relationship between T-score and Z-score for women of 65, 70 and 75 years old, 
living in Oslo [23]:
As shown by figure 4, a woman can have a BMD corresponding to osteoporosis but a normal 
value for her age [81].
Figure 4; T- and Z- score [81]:
The BMD values can be measured in several ways, each method has pros and cons and no 
method is suitable for measuring BMD in all parts of the body. The diagnostic categories 
suggested by WHO are based on BMD values measured by dual energy X-ray absorptiometry 
(DXA). Although quite expensive, this method gives high precision and low doses of 
radiation compared to the other methods available; quantitative ultra sound and quantitative 
computer tomography. Because of limited precision and low correlation between the 
different methods, BMD values from different methods should not be compared [81].
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1.3 Fractures
Osteoporosis is in itself asymptomatic, but manifests itself trough the related fractures. Most 
common are fractures of the hip, spine and forearm. Fractures can be seen as a function of a 
trauma and the fragility of the bones. Both these factors increase the probability of a fracture. 
It is possible to suffer a fracture with minimal trauma for patients who have very fragile 
bones. And it is of course possible for a healthy, young person to break a leg without being 
osteoporotic 
The main problem with osteoporosis is that, as the bones grow more fragile, the impact
needed for bones to break diminishes rapidly.
1.3.1 Societal impact of fractures
Scandinavia has the highest incidence of osteoporotic fractures in Europe [38].These 
fractures represent a considerable burden to the patients and to society as a whole, as  the 
fractures are associated with a significant increase in mortality, morbidity, loss of function 
[31] and health and social care costs [73]. It has been estimated that there are approximately 
9000 hip fractures in Norway each year and that the direct societal costs of these fractures 
amount to 1.5 billion NOK [50]. In the US osteoporosis related fractures were estimated to 
13.8 billion, of witch approximately 62% were spent on in-patient care, 28% on nursing 
homes and 10% on out-patient care [73].
The EU has estimated that the treatment costs of osteoporotic fractures will increase with 
more than 20% by 2020 [91]. 
It should be clear from the discussion above that osteoporosis related fractures pose a large 
burden on the health care system in the form of both capacity and money, both of which have 
an opportunity cost. In other words; these resources could have been spent on other patient 
groups, if the fractures had been avoided. 
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1.3.2 Patient outcomes
“Quality of life data obtained in patients with osteoporotic fractures show that loss of quality 
of life is more severe in patients after hip or multiple vertebral fractures than in patients’ with 
a single vertebral fracture or distal radius fracture” [51].
Hip fractures 
Hip fractures are the most serious of the osteoporosis related fractures, as they are the ones 
which are most strongly associated with loss of function, decreased quality of life, excess 
mortality and health and social care costs. Hip fractures are considered to be as big a treat to 
the health of old people as a heart attack or a cancer [12]. All people suffering a hip fracture 
will be admitted to a hospital for an operation and will also require physiotherapy. Many of 
the patients will have a permanently impaired functional level. Loss of function is an 
important element, as it to different degrees can limit the individual’s ability to lead an 
independent life. 
Hip fractures also have a significant negative effect on the individuals’ quality of life. 
“Quality of life depends on co- morbidity, mobility, activities of daily life, independence and 
fracture complaints” [51]. 
Qualities of life estimates after a hip fracture vary a great deal between different studies. 
Estimates ranging from 0.05 up to 0.885 have been reported in the literature. Possible 
reasons for this will be discussed further in chapter about quality of life.
Vertebral fractures
Vertebral fractures are divided into morphometric and clinical fractures. Morphometric 
fractures are defined as fractures identified by a change in the shape of a bone, rather than 
pain or other symptoms [82]. Clinical fractures are, as the name implies, fractures that come 
to clinical attention because the patient contacts their GP or other health care providers. 
There is however no consensus in the definition of vertebral fractures [17]. 
Research done by Kanis and co-workers [45] indicate that only 23% of vertebral fractures in
women in Malmo, Sweden came to clinical attention. The reason for this, is that unlike the 
hip fractures which often occur trough a fall from standing height [17], the vertebral fractures 
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can occur during daily activities, without any identifiable trauma [73]. The patients may thus 
be unaware that they have had a fracture, as the only symptom of an incident vertebral 
fracture may be back pain. 
Vertebral fractures often reoccur and multiple prevalent vertebral fractures are associated 
with impaired physical function, height loss, sleep disturbance, depression, fear of falling 
and loss of self esteem [73]. An incident vertebral fracture cause pain and the pain may last 
for three years or longer. Recurring fractures may cause vertebral deformity (kyphosis), 
which may again lead to loss of lung function, height loss and significant loss of function. 
Vertebral deformity may also lead to social isolation and depression, as a consequence of the 
decline in physical function and change in appearance [74]. Unlike the hip fractures 
however, the vertebral fractures have not been shown to increase the likelihood of moving to 
a nursing home.
We will in our model only look at clinical fractures, as costs, incidence and quality of life 
associated with morphometric fractures are very uncertain. 
Wrist fractures 
Wrist fractures cause considerable utility loss in the first few months, due to pain and loss of 
function. Most patients do, however fully recover within one year [12, 51]. 
Mortality 
Low BMD is associated with increased mortality. Increased mortality has also been 
documented after hip and vertebral fractures. Whether or not this post-fracture mortality is 
causally related to the fracture remains an unresolved question. For details see the chapter 
about BMD and mortality.
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1.4 Prevention and treatment of osteoporosis
The focus in this thesis is alendronate. This is however only one of many ways to prevent 
and treat osteoporosis. In this chapter we make a short summary of some of the options.
There are two main strategies in the prevention of osteoporosis and osteoporosis related 
fractures, and interventions can use either one or both. The first strategy targets the bone 
density, either by increasing the making of new bone or by decreasing the bone resorption. 
The second strategy is to prevent trauma, so called false prevention.
The prevention can be either primary or secondary. Primary prevention means that it is 
targeted at people with no symptoms or other detectable signs of disease, while secondary 
prevention means that it is targeted only at people at increased risk. 
Some of the strategies for prevention are based on medical interventions while others are 
non-medical, like promoting certain kinds of life style and diet.
1.4.1 Medical prevention and treatment
Several pharmacologic options are available. Strong evidence shows that supplement of 
calcium and vitamin D in combination reduce fracture risk in elderly women [81]. Calcium 
and vitamin D supplement can be used alone or in combination with other drugs. Hamdy 
emphasises that based on the available evidence, it is important to ensure calcium and 
vitamin D sufficiency in all patients. Calcium and vitamin D will not reduce the risk of 
vertebral fractures in women with symptomatic osteoporosis, but they will complement the 
anti-fracture efficacy of other drugs [31]. 
The other drugs are oestrogen, selective oestrogen receptor modulator (SERM), parathyroid 
hormone (PTH) and bisphosphonates. Oestrogen prevents loss of bone mass and reduces the 
risk of fractures [81]. It was previously used to prevent osteoporosis, but is no longer 
recommended as the primary choice of treatment by the Directorate for health and social 
affairs because of serious side effects like increased risk of breast cancer [92]. SERM 
reduces the incidence of vertebral fractures, but gives no significant reduction in other types 
of fractures. SERM also increases BMD, but the effect is smaller than the effect of oestrogen 
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and bisphosphonates [81]. Daily injections of PTH stimulate bone formation, and reduce the 
risk of new morphometric vertebral fractures by 65% in postmenopausal women with 
established osteoporosis. Non-vertebral fractures are decreased by 53%. PTH also increases 
BMD in hip and vertebra in elderly women with postmenopausal osteoporosis [81]. 
A much used option is bisphosphonates. According to Hamdy [30], the bisphosphonates 
alendronate and risedronate produce the most robust fracture risk reductions of all treatment 
modalities: approximately 40 to 50% reduction in vertebral fracture risk; 30 to 40% in non-
vertebral fracture risk; and 40 to 60% in hip fracture risk”. The Directorate for health and 
social affairs recommend bisphosphonates combined with vitamin D and calcium as the 
primary choice of treatment for osteoporosis for several groups of postmenopausal, 
Caucasian women [92]. 
Sales data
The use of bisphosphonates and other medicinal products that could be used for 
prevention/treatment of osteoporosis has increased since 2001. The sale of bisphosphonates 
has increased steadily during the last years. In 2005 it increased by 15% and totalled NOK 
194 million, pharmacy retail price. While bisphosphonates have increased, the sales of 
estrogens used in the menopause have decreased by 14% in 2005. Since 2001 there has been 
a total reduction of 45% for oestrogen. These changes in the sales could be results of the 
2003 recommendations from the medicinal authorities not to use oestrogens as first line 
therapy for prevention and treatment of osteoporosis. [93]
Alendronate is the most used bisphosphonate in Norway, and the amount sold increases 
every year. 7.87 doses of alendronate per 1000 inhabitants per day were sold in 2005, and 
8.23 in 2006. The second most sold bisphosphonate in 2006 was risedronate with 0.80 doses 
per 1000 per day [93].
1.4.2 Non-medical prevention  
In addition to medical treatment, several non-medical actions can be taken. Both sufficient 
energy intake and sufficient supply of vitamins and minerals have impact on BMD level and 
fracture risk since both low weight and low body mass index as well as malnutrition are risk 
factors for osteoporosis. The Norwegian guidelines for treatment of osteoporosis [92]
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recommend a diet which ensures a certain daily amount of calcium and vitamin D. Calcium 
increases BMD, and vitamin D is important for the absorption of calcium in the intestines 
[81]. 
Physical activity is important to build and maintain bone mass in individuals at all ages, and 
one possible reason for the growing incidence of osteoporosis is changed lifestyle with less 
activity than before. Evaluating the effects of physical activity on fracture risk and BMD can 
be hard because of confounding; other factors may influence the results. A physical active 
person might differ from a less active person in many other ways, for instance regarding 
smoking status and nutrition. Both the Swedish study and the Norwegian guidelines do 
however conclude that physical activity increases BMD and decreases fracture risk in 
postmenopausal women. The effect is somewhat more uncertain for women older than 65 
[81].
Protection against falling
Approximately 30 per cent of people above 65 years of age fall each year. The number is 
higher in institutions. Several factors, like reduced balance, reduced sight and hearing, 
insufficient nutrition and medication, can lead to falls. The risk of fracture after a fall 
increases when the person falling has osteoporosis [81]. Although less than 1 fall in 10 
results in a fracture, a fifth of fall incidents require medical attention. Several actions can be 
taken to reduce the incidence of falls in elderly people. Examples that are likely to be 
beneficial are certain kinds of exercise and home hazard assessment and modification for 
people with a history of falling [28]. Hip protectors aim to reduce the impact of a fall on the 
hip, and thus the risk of a hip fracture. Use of hip protectors reduces the risk of hip fractures 
for some groups of elderly people with high risk of falling, living in institutions [78].
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1.5 Economic evaluation and priority setting
“Most countries feel constant pressure because expenditure is increasing and resources are 
scarce” [62]. 
Figure 5:  The Health Gap [72]
A rapid technological development in medicine has made the gap between what is 
technologically possible and what society can afford widen [72].  
When resources are too scarce to accommodate all needs and wants, it is rational to prioritise 
something one values highly in relation to what it costs [64].The question then becomes, 
what does the Norwegian society value when it comes to health care? And what are central 
policy goals in this field?
Three policy documents have specifically addressed the issue of priority setting in the 
Norwegian health care system; NOU 1987:23 (“Guidelines for priority setting in the 
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Norwegian health care service”), NOU 1997:7 (“Pills, priority setting and policy”) and NOU 
1997:18 (“Priority setting revised”).  NOU 1987:23 [70] and NOU 1997:18 [71] were both 
general, in the sense that they applied to the entire Norwegian health care system, while 
NOU 1997:7 [72] was specifically targeted at pharmaceuticals and their reimbursement. 
According to NOU 1997:7 criteria for priority setting for pharmaceutical interventions were 
(in prioritized order):
The severity of the disease; A disease is considered severe to the degree that it causes pain 
and discomfort, loss of physical, psychological and social function and if it limits the 
individual in his or her daily activities. Severity is also evaluated according to the risk 
increase it imposes of death, disability and discomfort, if treatment is postponed.
The effectiveness of the treatment; Effectiveness of treatment should be well documented.
The cost-effectiveness of the treatment; The costs of the treatment should be in a 
“reasonable” relationship to the effects of the treatment.
The intention of the treatment; Interventions which aim to treat a disease is prioritised before 
preventive measures. Preventive measures are prioritised before quality of life 
improvements. 
This is in line with NOU 1997: 18, which also emphasises the weight on severity, effect of 
the treatment and a “reasonable” relationship between the costs and the effects [71].The 
same view is also expressed in the patient rights act of 1999, which states that a patient is 
entitled to necessary treatment if the expected effects are in a “reasonable” relationship to the 
costs [55]. 
The cost effectiveness of a treatment is investigated through an economic evaluation. 
Economic evaluations aim to aid policy makers in decision making, when it comes to priority 
setting. Economic evaluation is defined as “the comparative analysis of alternative courses of 
action in terms of both their costs and consequences” [19]. 
One type of economic evaluation is cost-utility analysis. In a cost-utility analysis, the effect 
of a treatment is measured in QALYs. The QALY attempts to capture both the morbidity and 
the mortality aspect of a specific disease or condition. An advantage with using a cost-utility 
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analysis and QALYs is that it makes comparison between different treatments and 
interventions for various diseases and conditions possible. 
One feature of the QALY is that it expresses the preferences of individuals over time spent in 
different health states. When priorities are set, the preferences reflected should be those of 
society as a whole. The question then becomes whether the sum of individual preferences, as 
expressed in QALYs, is the same as societal preferences. There are several reasons why there 
may be inconsistencies between implicit QALY judgements and societal values:
 Every level change is the same in the QALY approach; severity (starting point) is not 
taken into account. This means that in terms of QALYs, a health gain for a seriously
ill person and a nearly healthy person can give the same amount of QALYs. 
 Potential for improvement is given value in QALY calculations, but not necessarily 
in the eyes of the society.
 An intervention which prolongs life with ten years will give more QALY gain when 
given to a healthy person, than when given to a person with a handicap, as duration 
on QALY calculations is multiplied with the value of the health state. 
Considering that QALYs don’t necessarily reflect societal values, implies that results from a 
cost utility analysis should not be interpreted alone, but seen in relationship with other 
priority setting criteria. In other words, the fact that an intervention is cost effective does not 
necessarily mean that it should be implemented.
Treatment guidelines reflect society’s value judgements [27]. This implies that the treatment 
guidelines should reflect the criteria for priority setting as stated in policy documents.
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Figure 6: Flow chart from Norwegian guidelines for treatment and prevention of 
osteoporosis and osteoporosis related fractures [90].
The current treatment guideline for treatment and prevention of osteoporosis and 
osteoporosis related fractures [90] recommends that treatment with bisfosfonate is given to 
postmenopausal women who are considered high risks, that is women who have a t-score of 
less than -2.5 or women with a t-score between -1.6 and -2.5 who have  suffered a previous 
fragility fracture. Only women with a t-score of less than or equal to -2.5 with a previous 
fragility fracture will be reimbursed for their drug expenses.
Considering that osteoporosis related fractures, the hip fractures in particular, are associated 
with excess mortality, pain and suffering and that they in addition can have a significant 
negative impact on functional level, they can be viewed as fulfilling the first criterion for 
priority setting listed above, that is the severity criterion. The effect of alendronate is well 
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documented, at least in women with established osteoporosis. The question then becomes; 
for which groups of women is prevention of osteoporotic fractures trough treatment with 
alendronate cost-effective?
1.6 Research question
What are the incremental costs and effects associated with treating postmenopausal women 
aged 65, 70 and 75 years and T-scores equal to -2.5, -2 and -1.5 with alendronate 70 mg per 
week in addition to calcium and vitamin-D supplements, compared to calcium and vitamin D 
supplements alone?
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2. Method
2.1 Model
2.1.1 General about Markov
We have used a Markov model to simulate our cohort. Osteoporosis is a chronic disease 
which develops over time. Sonnenberg and Beck [83] state that Markov models are useful 
when a decision problem involves risk that is ongoing over time.  
2.1.2 Structure of our model
Our model can follow a cohort of 10 000 women from 50 until 100 years of age or until 
death. It consists of seven Markov health states: well, well after fracture, mild hip sequela, 
moderate hip sequela, severe hip sequela, vertebral sequela and death. In addition the model 
contains four temporary health states of first year sequelae.
All women start in “well” and can experience a hip-, vertebral- or forearm fracture during the 
first cycle. These are events which the individuals can pass through, but not spend any time 
in. Passing through an event accumulates disutility and costs.
After sustaining a hip fracture, a woman will have mild-, moderate- or severe sequelae. From 
the mild and moderate sequelae health states she can move to “well after fracture”. It is not 
possible to recover to “well after fracture” from severe hip sequelae. 
After vertebral fractures one can have sequelae or move to “well after fracture”. 
From all sequelae health states, it is possible to sustain new fractures of any kind, meaning 
that for example a woman in “moderate sequela hip” can still break her fore arm.
All women having a forearm fracture return to “well after fracture” at the end of the cycle. 
Women who do not sustain a fracture, can die or remain in the same state.
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Age dependent transition probabilities determine how the individuals move from one state to 
another. The transitions occur in one year cycles. 
“Death” is an absorbing state, meaning that it is not possible for an individual to leave this 
state once it is entered. 
Figure 7; Model Structure: Transitions possible in the first year. 
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2.2 Input probabilities
2.2.1 Incidence of fractures
The incidence of osteoporosis related fractures vary both within and between countries. 
Research indicate that the Scandinavian countries have a generally higher incidence than the 
rest of Europe [38].
Table 2; Incidence of fracture per 1000 person years [38]
The reason for the high hip fracture incidence in Scandinavia is not known, and can seem 
paradoxical considering the high dietary intake of calcium in this region. Possible 
explanations include; low exposure to sunlight during the winter months, slippery sidewalks 
and thus more falls, environmental and genetic factors.
Rural areas generally have lower incidence of fractures than urban areas within the same 
country. The reason behind this variation is unknown [17].
Bulajic-Kopjar and co-workers [10] studied differences in incidence of hip fracture between 
different counties in Norway. They found that the incidence rate varied from 8.1 per 1000 in 
Finmark to 14.0 per 1000 in Oslo. They found a clear regional pattern, where the counties in 
the south and south-east had the highest incidence rate [10]. Falch and co-workers also 
looked at geographical differences in fractures and found that incidence in Sogn og Fjordane 
was only 65% of the incidence in Oslo [22]. Given these great variations in fracture rates, it 
is important to choose incidence rates which are representative for the population simulated 
in a model used for economic evaluation.
In order to find the incidence of hip fractures in Norway, one possibility could have been to 
use data from The Norwegian Patient Register. Research undertaken by Lofthus and co-
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workers [53], do however indicate that register data have a low degree of validity. Lofthus 
and co-workers studied medical records of hip fracture patients in three hospitals in Oslo and 
compared the identified number of cases with the number in The Norwegian Patient 
Registers (NPR) database for each hospital. They found that the register-data underestimated 
the number of hip fracture patients treated at one of the hospitals with 46%, for the other two 
hospitals the NPR database overestimated the number of patients with 17% and 19%.
For the future modeller, the Norwegian Hip Fracture Register [63] may become a good 
source of incidence data, but we find it unrealistic to assume that the reporting routines to 
this register are working perfectly in so early on. The register started up 01.01.05 and we can 
only find data from 2005 published. The data from 2006 is likely to be of better quality, but 
these data are not available in time for thesis submission.
We do however have good data for Oslo, and we have decided to use the study by Lofthus 
and co-workers [54] as incidence input in our model. Given the variation between rural and 
urban areas, an extrapolation from the Oslo data to the entire country would most likely 
overestimate the hip fracture incidence in Norway. This would make treatment with 
alendronate seem more cost effective than it truly is. On these grounds we have decided to 
limit our model to Oslo for the time being. 
The input chosen for incidence of forearm fractures is new, not yet published incidence data 
from Oslo [52].
For vertebral fractures no valid data can be found from Oslo. Based on the advice from 
Cathrine Lofthus MD and Jan Falch MD at Aker Hospital, we chose to use incidence data 
from Malmo, Sweden [46]. According to our experts, the incidence in Malmo is a good 
estimator of the incidence in Oslo.  We have used the incidence of the first time clinical 
fractures for women in the relevant age range.
2.2.2 Fracture risk connected to BMD
For each standard deviation decrease in BMD measured at the hip, the risk of hip, vertebral 
and forearm fracture increase with respectively 2.6, 1.8 and 1.4 [57]. Our model does not 
permit for different BMD-risks connected to different types of fractures. We therefore used 2 
as an overall estimate of fracture risk connected to each standard deviation in BMD. We used 
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this number in combination with table 1 in order to calculate the increased fracture risk for 
the nine different groups of women.
2.2.3 Distribution between and duration of sequelae
We have in this model defined “severe sequela” as impairments in functional level, which 
are so severe that patients in this health state will require long term care in a nursing home. 
According to the study by Osnes and co-workers [76], 17% of patients who lived at home 
before the hip fracture, will move to a nursing home after the fracture. This is close to the 
result found by Melton [58], who reported 19%. Finsen and co-workers [26] found that 21% 
of the patients were bedridden after a hip fracture.  We assume that all bedridden patients 
will require long term care in an institution. We chose to use Osnes’ more conservative 
estimate of 17%. 
We defined “moderate sequelae” as needing assistance in the home from either family or a 
home help service. Osnes and co-workers [76] found that 55% of the patients who did not 
receive any help pre-fracture, needed help post-fracture. This number is much larger than the 
one found by Melton [58], which was 10%, but  close to the one used by Christensen and co-
workers [13], which was 60%. We chose to use the result found by Osnes and co-workers of 
55%.
As we assume that all patients suffering a hip fracture will have some sort of sequelae, this 
means that 28% will go to “mild hip sequela”. Mild sequela in this setting will mean some 
pain and discomfort, but not enough to limit the patients’ independence.
As seen from figure /, all patients who have sequela will be in a “sequela 1” health state in 
the first cycle. While we assume that the patients who move into a nursing home will stay 
there for their remaining lifetime, patients in mild or moderate sequela are able to recover 
and move to the “well after fracture” health state. 
While in a sequela health state, a patient can suffer a new hip-, vertebral or wrist-fracture, 
they can remain in sequela and move onto sequela two, they can become “well after fracture” 
or they can die. We have not modelled the patients who have a previous fracture as having 
any increased risk of fracture.
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The probability of remaining in “moderate hip sequela” is assumed to be 50%. The 
probability of remaining in “mild hip sequela” is assumed to be 10%.
We have used the same assumption as Christensen and co-workers [13] and assumed that 
25% of patients with incident vertebral fractures will have vertebral sequela and that the 
probability of remaining in vertebral sequela is also 25% .
2.2.4 Probabilities of “well” health states
The probabilities of remaining in “well” or “well after fracture” depend on the probabilities 
of new fractures. Likewise, if a person starts in a sequela health state, the probability of 
becoming “well after fracture” depends on the probability of remaining in the sequela health 
state and of the probabilities of new fractures.
2.2.5 Effect of alendronate
Effect can be expressed in several ways. Efficacy is measured under ideal circumstances, i.e. 
when the patients fully comply with the associated recommendations while effectiveness is a 
measure of effects when the patients are in real life circumstances. Effectiveness includes 
efficacy, but in addition it takes into account the acceptance by those to whom the treatment 
is offered. Data on effectiveness are preferred to data on efficacy in economic evaluation 
studies, but they are hard to obtain and may not be available [19]. Randomized controlled 
trials measure efficacy as the patients are followed up carefully. 
To find literature on effect of alendronate, we searched Cochrane and found two relevant 
meta-analyses [15, 77] and several clinical trials. We found no studies from Norway, Sweden 
or Denmark, so we chose to use studies from other countries than the Scandinavian. While it 
is not recommended to transfer data on costs between different countries, data on 
effectiveness can more easily be transferred as long as there are no important differences in 
biologic factors and treatment patterns [99]. We excluded studies which include other patient 
groups than postmenopausal, Caucasian women, and articles which compare different 
treatments. We use relative risk reduction as measure of effect. We found no studies of 
effectiveness, all the studies we found are studies of efficacy.
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Several of the relevant hits were based on the Fracture Intervention Trial (FIT). The FIT 
study was conducted at 11 clinical centres around the United States. It was a randomised, 
blinded and placebo-controlled trial, designed to test whether alendronate reduces the risk of 
fractures in women aged 55-80 years with low hip bone marrow density [2]. 6457 women 
were included and assigned to one of two sub studies; the Vertebral Deformity Study which 
included women with at least one previous vertebral fracture, and the Clinical Fracture Study 
which included women without previous vertebral fractures. The women were given 5 mg 
alendronate per day for two years, followed by 10 mg per day for the rest of the trial. Only 
the clinical fracture arm is relevant to us, as our study concerns women with no previous 
fractures. 
In one of the articles based on the clinical fracture arm of the FIT study [16], alendronate 
increased BMD at all sites studied and reduced the risk of clinical fractures by 36% (RR 
0.64, CI 0.50-0.82) in women with T-score equal to or less than -2.5. No statistically 
significant reduction was observed for hip fractures or forearm fractures or in those with T-
score above -2.5. The risk of clinical vertebral fractures is not reported.
The meta-analysis by Cranney and collaborators [15] includes 11 trials that randomised 
women to alendronate or placebo and measured bone density for at least one year. They 
found among other things a pooled relative risk of 0.52 (CI 0.43-0.65) for vertebral fractures 
in patients given 5 mg or more per day of alendronate. Forearm was reduced by 52% (RR 
0.48, CI 0.29-0). No statistically reduction was found for hip fractures. 
The meta-analysis by Papapoulos and co-workers [77] proves a consistent effect of 
alendronate on hip fracture reduction among populations of different ages and differing 
levels of BMD. Relative risk reduction was 0.45 (CI 0.28-0.71) in patients with T-score of    
-2.5 or less. 
Christensen and collaborators [13] assumed that alendronate reduce the risk of fracture by 
50%. This corresponds well to what we found from our literature search. On the basis of 
these studies, we also ended up assuming that alendronate reduces the risk of all fractures by 
50%. The risk reduction is varied in the sensitivity analysis. We chose to use the confidence 
interval for overall risk reduction (0.32-0.66) from the meta- analysis of Cranney and co-
workers as our lower and upper value.
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Table 3; Effect of alendronate
There are several important factors to consider when the effect of alendronate is to be 
measured. These include dosage, age, treatment duration, effect after discontinuation,
adverse effects and adherence.
Dosage
The effect varies with dosage, and in their meta analysis Cranney and collaborators [15]
found that effect sizes were smaller in all fracture categories for dosage of 5 mg than for 10-
40 mg of alendronate. The FIT study used a dosage of 5 mg per day for two years followed 
by 10 mg per day for the remainder of the trial [16]. The Physician desk reference [79]
recommends a dosage of 10 mg per day or 70 mg once a week. According to Falch the latter 
is the most usual dosage. We chose to use a dosage of 70 mg once a week and assume that 
this dosage has the same effect as what was found in FIT where a daily dosage was used.
Age
When it comes to age, another article based on the FIT study studied the effect of alendronate 
on the age specific incidence of symptomatic osteoporotic fractures, and found that the 
relative risk reduction was consistent among women aged 55-80 [34]. Based on their 
conclusion, we assume constant risk reduction of alendronate for all age groups included in 
our study.
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Treatment duration
The effect of alendronate also varies with treatment duration. Several recent studies concern 
this topic, but there is still uncertainty around what is the optimal treatment duration. Briot
found that gains in BMD still persisted after 10 years of treatment with alendronate, but 
conclude by recommending treatment for four to five years, as no proof of fracture 
prevention with further treatment exists [8]. Black and co-workers [3] came to a similar 
conclusion; that discontinuing alendronate after five years had a small decline in BMD, but 
no higher fracture risk other than for clinical vertebral fractures compared with those who 
continued alendronate. According to Jan Falch MD at Aker hospital eight years is considered 
to be optimal treatment duration, but patients tend to stop taking the drug after a while. This 
low adherence makes it unrealistic to assume treatment duration of eight years, and Falch 
recommended using four years. This goes well with the FIT study which had an average 
treatment duration of 4.2 years [16]. 
Effect after discontinuation
The effect of alendronate will persist after discontinuation. In the long term extension of the 
FIT study, the effect on BMD and bone turnover was found to persist for up to three years 
after stopping treatment [20]. A later study from the same group concludes that 
discontinuation of alendronate after five years for up to five more years does not significantly 
increase fracture risk [3]. Based on this we assume that the effect of alendronate persists for 
three years after discontinuation. In the sensitivity analysis we vary this from no effect in the 
years after discontinuation and up to full effect for five years after discontinuation.  
Adverse effects
Like any other drug, alendronate has adverse effects. According to the Physician desk 
reference [79] more than 1/100 of patients treated with 10 mg alendronate per day have 
gastro intestinal problems like abdominal pain, nausea and heartburn; more than 1/1000 have 
problems like oesophagitis and oesophageal ulceration, and less than 1/1000 have problems 
like oesophageal blockage or perforation. Weekly administration of alendronate instead of 
daily can reduce gastro-oesophageal discomfort [4]. Other adverse effects can be bone- and 
joint pain, muscle pain and headache [79]. Osteonecrosis of the jaw associated with long 
term use of alendronate has been reported, but in most of the cases it happened after high-
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dose intravenous therapy to treat cancer [8]. We were not able to identify any studies which 
showed statistically significant results of gastrointestinal side effects. The reason why none 
of the results are statistically significant could be that the samples of the studies are too 
small. Adverse effects happen rarely, and for rare events it takes large samples to get 
significant results. We have not included adverse effects in our model.
Adherence
For various reasons, patients do not always take a drug as prescribed. The full benefits of 
medication can not be reached if adherence is low. According to Rossini and collaborators
[80] poor adherence has been reported with rates close to 50% for chronic conditions 
considered “clinically silent” to the patient. They found that the most frequent reasons for 
discontinuation of treatment were side effects, fear of side effects and lack of motivation for 
treatment. Poorly compliant patients had lower BMD and greater risk of fracture than 
patients adhering to the prescribed therapy. Patients who were prescribed to take alendronate 
weekly were found to have a higher adherence than those prescribed to take it daily; 6.9% 
versus 20.9% respectively had stopped treatment after 12 months. 
2.2.6 Background mortality
We found age and gender specific mortality rates for 2006 at the webpage of Statistics 
Norway [84]. Table can be found in the appendix.
2.2.7  BMD and mortality
We searched Medline and Embase using the combination of “bone density” and “mortality”. 
In Embase this resulted in 328 hits, four of which were relevant [9, 40, 42, 97]. 
Browner and co-workers [9] followed 9704 women from Oregon, US over 2.8 years and 
found that the relative risk of mortality was 1.19 per standard deviation decrease in BMD. 
BMD in this study was measured in the underarm (proximal radius bone).
The Rotterdam study [97] also looked into the association between BMD and mortality. 
BMD was measured in the hip. They found no significant relationship between BMD and 
mortality in women. 
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Kado and co-workers [42] followed 6046 prospectively for 3.2 years. After correcting for 
age, baseline BMD, diabetes, hypertension, incident fractures, smoking, physical activity, 
health status, weight loss and calcium intake, they found that each standard deviation 
decrease in BMD was associated with a 1.3 fold (95% CI 1.1-1.4) increase in total mortality.
The relationship between mortality and BMD has also been studied in a Swedish population 
[40]. In this study 1924 individuals, 1074 of which were women, from Gothenburg was 
followed for seven years.  Johansson and co-workers found that one standard deviation 
decrease in BMD was associated with a relative risk of dying of 1.39 in both men and 
women. BMD in study was measured in the heel (calcareous).
We chose to use the result from Johansson and co-workers. The reason for this choice was 
that the follow-up time in this study was twice that of the other studies. We also considered 
that that mortality associated with BMD might be related to the prevalence of osteoporosis, 
as it has been found that mortality after hip fractures vary between areas with high and low 
incidence [49]. In this respect it seemed appropriate to choose a study from an area with a
similar incidence as in Oslo.
 The risk increase for the different groups was calculated using table 1 and the findings of 
this study.
2.2.8 Incident fractures and mortality 
Osteoporosis related hip and vertebral fractures are highly correlated with excess mortality 
[48]. For hip fractures, most of the mortality increase occurs in the first year following the 
fracture. Mortality thereafter declines, but remains higher than the general population [47]. 
Mortality following vertebral fractures follows a somewhat different pattern. The excess 
mortality in the first year is not as high as for hip fractures, but it remains higher than the hip 
fracture excess mortality in the long run (one year and onwards).
Hip
The relationship between hip fractures and excess mortality has been studied in a Norwegian 
population. Meyer and co-workers [59] followed 248 hip fracture patients and their controls 
for three and a half years with respect to mortality. They found that otherwise healthy and fit 
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hip fracture patients did not have increased mortality following their fracture compared to 
their controls. Excess mortality following a fracture was limited to patients with reduced 
mental status, reduced somatic health and low physical ability.
Farahmand and co-workers studied the impact of co-morbidity on the mortality after hip 
fractures. The used followed a set of 2245 incident hip fracture patients and 4035 controls 
over five years. They found that after adjusting for age and previous hospitalization 
(indicator of co-morbidity), the relative risk of mortality for hip fracture cases versus 
controls, was 2.3 (95% CI 2.0-2.5). The highest risk were found in the first six months after 
the fracture, where the relative risk was 5.7 [25].
We chose to use a relative risk of death of 1.25 for the hip fracture patients. This is the value 
used in DOOM and lies between the value found by Meyer and the value found by 
Farahmand.  In our model, we will reverse part of the excess mortality after hip fractures, and 
choosing the value found by Farahmand could thus make the treatment look more effective. 
We will vary this parameter in the sensitivity analysis, in order to see if this choice has any 
impact on the result.
Vertebral
Kado and co-workers [43] found that women with at least one new vertebral fracture had an 
age-adjusted excess mortality of 32% compared to those without incident vertebral fractures. 
However, after adjusting for potential confounders, there was no longer any significant 
difference between the groups. This result is similar to the findings of The European 
Prospective Osteoporosis Study (EPOS), which looked at mortality associated with vertebral 
deformity [37]. They found only a modest excess mortality in women with vertebral 
deformity, after age adjusting, but this difference was no longer significant when they 
adjusted for smoking, alcohol consumption, general health, previous hip fracture, body mass 
index and steroid use.
The European Vertebral Osteoporosis Study (EVOS) also studied the relationship between 
prevalent vertebral deformity and mortality. They found an association between the two, 
even after controlling for confounders. For women 65 years old, they found that the ones
with a vertebral deformity, had a relative risk of 2.2 compared to the mortality the women 
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without [32]. This study had a longer time frame, but smaller sample size than the EPOS 
study.
Due to modelling difficulties, we have not included any excess mortality after vertebral 
fractures in our model. We will discuss the implications of this limitation in the discussion.
2.2.9 Deaths causally related to fractures
The core question here is whether or not the relationship between the fractures and the excess 
mortality is a causal one. In other words; are the fractures causing women to die prematurely 
or are the fractures simply an indicator of a poor general health status? And what percentage 
of the excess deaths can be prevented by preventing the fractures? There is a clear potential 
for confounding here, as many of the risk factors for osteoporosis, such as smoking, 
inactivity and alcohol consumption are also risk factors for other diseases or conditions, like 
for example  cancer and cardio vascular diseases.
The distinction between causally related and associated mortality is an important one when it 
comes to economic evaluation of preventive measures, as only the causally related deaths 
have the potential of being postponed by preventing the fractures. Reversibility of causally 
related deaths is a common assumption in economic evaluations of fracture prevention [48].
There is however no empirical evidence to support this assumption.
“The extent to which early prevention for osteoporosis might avoid some of these deaths is 
unknown” [41].
“There are, however, no empirical data to indicate that there is indeed a survival advantage 
associated with the prevention of fracture” [48].
As pointed out by Kanis and co-workers, one would need a very large sample in order to find 
significant results in an empirical trial of the reversibility of deaths associated with prevented 
fractures [48].
In our model we will assume that part of the causally related excess mortality after hip 
fractures can be reversed by preventing the fractures. The reason for this partial reversal is 
that we believe that women avoiding a fracture are likely to die in from other causes.
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Hip
Farahmand [25] states that much of the increased mortality after hip fractures seems to be 
due to the interaction between the fracture event and pre-existing co-morbidity, but that the 
fact that the relationship is found even in women with no apparent co-morbidity suggests that 
at least some part of the excess mortality is causally related to the fracture.
Kanis and co-workers studied excess mortality after hip fractures by using register data from 
Sweden. They assumed that the excess mortality after a hip fracture was a function of 
causally related deaths and pre-existing co-morbidity. They estimated that 24% (17-32%
depending on age) of the deaths following a hip fracture were causally related to the fracture 
itself. The fraction was dependent upon and increased with age [48]. We will use the 
estimate of 24% as input in our model.
Vertebral
Johnell and co-workers [41] followed a somewhat different approach. They assumed that a 
high mortality immediately after the fracture was a function of both co-morbidity and 
causally related deaths, while the long term (one year and onwards) mortality was mainly due 
to co-morbidity. They calculated that there was a significant and high mortality associated 
with clinical vertebral fractures and that the risk increase was as large as for hip fractures. 
Their estimate was that 23% of the deaths in the first year after a vertebral fracture were 
related to the fracture itself.
Kanis and co-workers [47] studied excess mortality after hospitalisation for vertebral 
fractures. The study was based on register data from Sweden. They found that 28% of all 
deaths associated to the fracture were causally related.  According to these authors, the 
estimates of mortality associated with vertebral fractures vary both with the time frame and 
the definition of vertebral fractures used in the different studies.
We will not include any deaths causally related to vertebral fractures in out model, due to 
modelling difficulties.
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2.3 Input payoffs
2.3.1 Costs
To identify articles on costs related to osteoporosis and fractures we searched EMBASE and 
Medline using the Mesh-terms “health care costs”, “osteoporosis”, “hip fracture”, “vertebral 
fracture”, combined with “Norway”, “Sweden” and “Denmark”. This resulted in no relevant 
hits on Norwegian costs, but two Swedish ones. They both use a societal perspective and 
include both direct and indirect cost. One of them assessed the costs related to hip, vertebral 
and wrist fractures in 635 male and female patients for one year after the fracture [5]. The 
other followed 1080 menopausal women admitted for primary hip fracture surgery in 
Stockholm in 1992 and collected costs for one year before and one year after the fracture 
[100]. In addition to these studies we used Christensen and co-workers [12].
According to Drummond [19], the theoretical proper price for a resource is the opportunity 
cost, defined as the value of the forgone benefits because the resource is not available for its 
best alternative use. In lack of opportunity costs we have to use other kinds of costs, like 
average cost per patient and market prices. We used among other things the Norwegian fee 
schedule for GPs [66], Norwegian DRG prices [89] and data from Statistics Norway [85]. 
Using market prices unadjusted may lead to bias as they do not necessarily reflect marginal 
costs because of market imperfections in health. To account for this, certain adjustments are 
made, like subtracting value-added tax, as this is not a cost to society, but a transfer. Another 
thing we did, based on personal communication [39], was to assume that co-payment and 
reimbursement cover 40% of the total costs for out-patient clinics. 
The estimation of costs has three steps, identifying cost components, quantifying them and 
valuing them in monetary terms [19]. Using Christensen and co-workers [12] for the first 
two steps, we decided to do the third step in the cost estimating process, the costing, based 
on Norwegian tariffs. All costs are expressed in 2006 Norwegian crowns (NOK). Our costs 
reflect, as far as possible, the societal perspective chosen for our analysis, meaning that all 
costs to whomsoever they accrue (the patient, hospital, society etc.) are included [19].
37
Both the article by Borgström and the article by Zethraeus include costs only for the first year 
after fracture. For our model we also need costs of subsequent years for the patients having 
sequelaes. Christensen and co-workers estimated the costs of all fractures, including 
sequelaes [12]. We used their article to identify and quantify the costs related to the different 
events and health states. Their numbers are partly based on empirical data and partly on 
expert opinions. We made some changes, based among other things of a Norwegian study of 
consequences of hip fractures [76] and on expert opinions. Christensen and co-workers used 
Zethraeus [100] for costs of hip fractures first year, and we decided to use the same, adjusted 
for inflation and currency [65]. 
Drummond emphasises that the more important the cost item is for the analysis, the greater 
effort should be made to estimate it accurately. Important costs in our analysis are the 
treatment costs as they concern all individuals. To be sure that these costs are as correct as 
possible, we asked for expert opinion on both identification and quantification of resource 
use related to treatment with alendronate. For cost of alendronate we used the price from 
Physician Desk Reference [79] of the least costly alternative. Costs of treatment with vitamin 
D and calcium are left out as they apply to all individuals and will not affect the choice 
between the two programmes.
Transferring costs between countries can be problematic due to differences in resource use 
and price levels between countries [99]. In lack of Norwegian data, we still chose to use cost 
data from the Sweden and Denmark although there are differences also between the 
Scandinavian health care systems. 
Costs are discounted to reflect a positive rate of time preference. Guidelines for economic 
evaluations from NMA suggest using a discounting rate between 2.5-5%. We discount at 4% 
in our analyses. 
Productivity costs and indirect costs like costs of informal care are not included. 
In the sensitivity analysis lower and upper boundaries were assigned to all costs by using 
70% and 130% percent of the estimates of total costs found in table 4. The discount rate was 
varied by using 0% and 7% as boundaries.
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Total costs are presented in the table below. Details on how the costs were calculated can be 
found in appendix 1.
Table 4; Total costs of events, health states and treatment with alendronate
2.3.2 Quality of life
Theory
“In the QALY approach, the quality adjustment is based on a set of values or weights called 
utilities, one for each possible health state, which reflects the relative desirability of the 
health state” [19].
As seen in the quote from Drummond, two things are needed in order to find a QALY 
weight; a health state and the value attached to the specific health state 
Health state profiles
“Health state profiles are instruments that attempt to capture all important aspects of HRQL” 
[29].
Health state profiles are elicited through a questionnaire. Each questionnaire will contain a 
number of dimensions, e.g. pain, ability to perform daily activities and so on. To each 
dimension, there are different levels, e.g. no problem or severe problems. Different 
39
questionnaires will contain different dimensions and levels and will result in various possible 
numbers of health states.  The number of possible health states in each questionnaire will be 
a function of the number of dimensions and levels. Number of possible health states equals 
the number of levels to the power of number of dimensions [19].  
A quality of life instrument may be specific or generic. In the literature, only generic 
questionnaires are described as health profiles. 
Generic instruments are designed to capture not only symptoms, but to what degree different 
symptoms affect the patient in his or her daily life. The advantage to using a generic 
questionnaire is that it makes comparison across diseases and conditions possible [61]. 
Specific instruments may be designed to capture the problems or symptoms connected to a 
specific disease, population, function or condition [29]. The advantage of a specific 
instrument is that it will contain dimensions which are central to the area in question. It 
follows from this that specific questionnaires may be more responsive to change in the 
patients’ health. Specific instruments are also closely related to clinical practise [29].
Several instruments have designed specifically for osteoporosis. Most of these focus 
specifically on the impact of vertebral fractures.
Figure 8; Osteoporosis Specific Questionnaires [96]:
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Multi Attribute Utility Instruments (MAU):
Multi attribute utility instruments (also referred to as preference instruments) are instruments 
which contain both a generic health profile questionnaire and a table of population-values 
connected to each health state profile. 
Figure 9; Structure of MAUs [96]:
Different MAUs are combinations of different questionnaires and different value sets. The 
value sets will differ both in the elicitation method used (TTO, VAS or SG), the population 
sample from which the preferences are elicited and scoring algorithms used [19]. It is 
important to realize that the results from different MAUs may not be directly comparable due 
to these diversities. Some widely used MAUs are EQ-5D (also referred to as the EuroQoL), 
SF-36, HUI and 15D.
Table 5; Characteristics of different utility instruments: [19, 33, 87, 96]
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Choice of input:
We needed three types of input for quality of life in our model; population norms, utility loss 
connected to the fracture events and utility connected to long term effects after fracture 
(sequela). 
Population norm utilities will be assigned to all persons in the “well” and “well after 
fracture” health states. All time spent in these health states will generate QALYs equal to the 
ones found in the general population. When a person suffers a fracture, we will assign a 
utility loss to this event, in order to reflect the short term pain and discomfort connected to 
the fracture. Utility loss connected to these events will be counted one time only, as it is not 
possible to spend time in the events. The utility loss connected to events will be multiplied to 
the population norm values. This means that for example a hip fracture, will be more 
burdensome the older the person is. 
Many people will suffer long term effects of the fracture, in the form of reduced functional 
level. This is modelled in the sequelae health states. We thus need to assign utility values to 
the sequelae health states, which reflect the reduced quality of life for persons in these health 
states. As in the fracture events, the utility loss is multiplied with the population norms.
Population norms
We will assume that patients have population norm (“normal”) quality of life before a 
fracture occurs. This may not be a valid assumption, as our population may be more likely to 
suffer from co-morbidity and may thus have lower quality of life than their matched age and 
sex group. 
Quality of life reflects the value or desirability connected to a specific health state. It is 
therefore conceivable that quality of life may vary across time and place, as it can be seen to 
reflect cultural attitudes. We therefore aimed to use population values elicited from a 
Scandinavian population if possible. 
We searched Medline and Embase using the mesh terms “quality of life”, “population 
research” and “rating scale”, which gave us 0 hits in Medline and 124 hits in EMBASE.
Based on the fact that we wanted general population values and not values connected to a 
specific disease or condition and that we wanted a Scandinavian population, we were left 
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with two studies; one by Lundberg and co-workers [56] and one by Burstrøm and co-workers
[11].
Lundberg and co-workers elicited values from a sample from Uppsala County trough a 
questionnaire containing a rating scale and a time trade-off. Out of the 8000 questionnaires 
they sent out, they received 5404 in a usable form. In the study undertaken by Burstrøm and 
co-workers, a representative sample was drawn from Stockholm County. They sent out 4950 
questionnaires and received 3112. The values were elicited trough the EQ-5D classifier and a 
rating scale.
Table 6; Population norms from Sweden [11, 56] :
Rating scale values are excluded.
We chose to use the population norms Lundberg and co-workers, as this was based on a 
larger sample than the study by Burstrøm and co-workers. We also believe that a TTO 
measurement is more in line with population preferences than one from EQ5D. 
Empirical estimates of utility values for osteoporosis-related health states
Utilities from systematic reviews
We searched Medline and EMBASE using the terms “Quality of Life” combined with 
“osteoporosis” or “hip fracture” or “spinal fractures”. This gave us 1351 hits in EMBASE. A 
search in the Cochrane database gave us one additional hit; Kanis et al. 2002 [44].
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We found three systematic reviews over osteoporosis-related utility values; one by Brazier 
and co-workers [6], one by Kanis and co-workers [44]and one by Stevenson and co-
workers[86]. All of these studies contained studies with a vide range of utility values after 
osteoporosis-related fractures. 
In the article by Brazier and co-workers [6] the utilities after a hip fracture ranged from 0.05 
up to 0.885. The very low value was found in a study by Salkeld and co-workers, where 
older people at risk of fracture valued a health state described as a “bad” hip-fracture, which 
included living in a nursing home. The high value was found in a NOF review, and was 
based on the judgement of an expert panel. 
Kanis and co-workers [44] also found a large variation in the utilities connected to a hip-
fracture. Here the utilities varied from 0.28 to 0.72. These utilities were both from the same 
study. The lowest value was given by a sample with a mean age of 68 years, who valued a 
hypothetical, disabling hip fracture state trough a TTO exercise.  The high value was given 
when patients who had previously experienced a hip fracture valued their own health state on 
a visual analogue scale. 
The articles all discuss a number of possible reasons for the vide range in utilities. The 
reasons are closely connected to what we have described above and we therefore only give a 
brief description of the individual points.
 Descriptive system of health states/Health profiles:
What method is used to describe the health state? Alternatives are a disease specific or 
generic profiles or vignettes. Who is presented with the disease description? Are the patients 
asked to describe their own, current health state or is a group of people asked to value a 
hypothetical description of the state? 
 Valuation technique:
Which method is used to put a value on the different health profiles? The most used methods 
are SG, TTO and VAS. These methods often give different values for the same health states; 
values found trough SG is generally larger than those found by TTO, which is again larger 
than VAS values.
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 Choice of anchor states:
The question here is what equals one and what equals zero in the valuation of health states. Is 
zero death or worst imaginable health state (negative utilities are conceivable for health 
states considered to be worst than death)? Is one full health or best imaginable health? 
 Source of values: 
Who are the values elicited from? Are the patients valuing their own health state, is an expert 
opinion being used or is a sample of the general population represented by a description of 
the health state in question? Research has shown that patients often put a higher value on 
their own health state than the general population do. 
 Approach for estimating the health loss from an event:
Which value is put on the patients’ pre-fracture health state? Two approaches are widely 
used; to assume pre-fracture utility of one or to assume that pre-fracture utility is equal to 
that of some control group.
Utilities from Swedish studies
We also preformed a search where we combined “osteoporosis” and “Quality of life” with
Norway, Sweden or Denmark.  This last search gave us three hits in Medline, two of which 
were relevant Kanis et al. 2002 [45] and Borgstrom et al. 2006 [5]. 
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Table 7; Utilities after hip fracture
As seen from the table, a wide range of utility values after hip fracture have been found. We 
wanted to choose utilities which were as high as possible, in order to get a conservative 
estimate of the cost effectiveness ratio. We were initially concerned that choosing an 
estimate based on EQ-5D would give too low a value [14], but based on the above table this 
does not seem to be the case here.
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We chose to use the estimate found by Borgstrøm and co-workers [5] for the utility 
connected to the fracture event, as this was the highest value reported value after 12 months 
and also the one with the largest sample size. 
For the long term effect of the hip fracture (sequelae) we chose the value found by Tosteson 
and co-workers [95], measured after more than 24 months. The sample size in this study was 
small, but still it was the most conservative estimate. 
Table 8; Utilities after vertebral fractures
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We followed the same reasoning when choosing utilities for vertebral fracture events and 
sequela; we wanted the highest, most conservative estimate we could find. We chose the 
value reported by Tosteson after 12-24 months for the fracture event and the value after more 
than 24 months for the fracture sequela. 
Table 9; Utilities after forearm fractures
For forearm fracture, we chose the estimate from Dolan and co-workers, as this value was 
higher than the one reported by Borgstrom and co-workers.
Table 10; Choice of multipliers for events
Multipliers are calculated based on information found in the articles. For details, see 
appendix.
We need to assign different utilities to the different hip fracture sequelae. In order to this, we 
will assume that patients in moderate sequelae have the reported mean utility. We will 
further assume that patients in mild sequelae have utility one standard error above the mean 
and that patients in severe sequelae have utility one standard error below the mean. This 
assumption implies that 67% of the patients will be in moderate sequelae. This is somewhat 
above what we have previously assumed (55% in moderate sequela). Still it is the best we 
can do without any empirical data.
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Table 11; Choice of multipliers for sequelae health states
Multipliers are calculated based on information found in [95]. For details see appendix.
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2.4 Model parameters
The table below includes all parameters and the values used in the base case analyses.
Table 11; Model parameters
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3. Results
Our base case consisted of nine groups of women, constructed from the chosen ages and T-
score levels. The Markov model was used to estimate the cost effectiveness of alendronate in 
the different groups. 
The average life time osteoporosis related costs for a 65 year old woman with T-score of -1.5 
was estimated to be approximately NOK 229 000 in the control group and 210 000 in the 
alendronate group. Similarly, average life time QALYs amounts to 9.952 for the women in 
the control group and 9.970 for those in the alendronate group. This entails that treatment 
with alendronate is cost saving and more effective; giving alendronate to one patient implies 
a saving to the health care system of approximately NOK 19 000 and a QALY gain of 
approximately 0.018 QALY. Alendronate is in other words a dominant strategy. All nine 
groups in the base case had similar results: treatment with alendronate was less costly and 
more effective to the health care system. 
The average QALY gain per patient treated with alendronate is rather small in all groups. 
However, when aggregated to societal level, the QALY gain would be of significant impact 
because of the large size of the group. 
Table 12; Results Base Case
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Sensitivity analysis
Because of uncertainty around the parameters, a one-way sensitivity analysis was performed 
to see whether the conclusions would be altered by any change in the parameters. Lower and 
upper bounds were assigned to every parameter, and then one-way sensitivity analyses were 
performed on all variables.
The sensitivity analyses showed that the conclusion is robust to changes in the parameters. 
Increasing the discount rate of costs to 7% gave a cost per QALY of 125 813. Treatment with 
alendronate was still cost saving when the other parameters were changed one by one. 
Table 13; Results from the one-way sensitivity analysis
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Extreme cases
The one-way sensitivity analysis showed that, with the exception of increasing the discount 
rate of costs, changing one variable at the time was not enough to alter the conclusions from 
the base case analysis. We wanted to see how changing several variables in disfavour of cost-
effectiveness at the same time would influence the results, and constructed two scenarios or 
extreme cases. First we set the risk reduction of alendronate to 0.75 and changed back to the 
distribution of sequelae used in DOOM. For women aged 65, with T-score of approximately 
1.5, these changes resulted in an ICER of NOK 147 753. Second; for the same group of 
women, using the price of alendronate from before the patent ran out in addition to the old 
distribution of sequelae, gave an ICER of NOK 752 647. The ICERs, or the costs per QALY 
gained in these cases are positive, which means that treatment with alendronate is not cost 
saving anymore.
This shows that changing more than one parameter at a time may influence the conclusion. 
Ideally we would have performed a probabilistic sensitivity analysis, but time did not allow 
us to do this.  
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4. Discussion
The main findings of this study suggest that, from a broad health care perspective, giving 
alendronate in addition to calcium and vitamin D supplements, to Norwegian, 
postmenopausal women of age of 65, 70 and 75 and T-score equal to -1.5, -2.0 and -2.5, may 
be more effective and less costly than treatment with calcium and vitamin D supplements
alone. There are several limitations of the study, however, due to assumptions and 
uncertainties around the parameters, and the results must be interpreted with these limitations 
in mind. In this chapter we discuss the assumptions and limitations, and how they have 
possibly influenced the conclusions. 
4.1 Assumptions and limitations
Indirect costs
Indirect costs like productivity costs and costs of informal care are not included. Our study 
concerns elderly women above 65 years of age, and as most women of this age are retired, 
productivity losses due to fractures for this group will probably not be substantial. Informal 
care is more relevant as many of the fracture patients still live at home but are in need of help 
to manage daily activities. We have assumed that the women in “moderate hip sequela” will 
receive home help. We do, however, believe that they in addition will need informal care 
from friends, relatives etc. We have not been able to identify any studies on costs or amount 
of informal care due to fractures in Norway. In addition, as there is little consensus on how to 
measure and value these costs, and whether to include them at all [19], we chose to leave 
them out. 
The exclusion of indirect costs like informal care and productivity loss leads to an 
underestimation of the total societal costs of fractures and sequelae. It means in fact that 
alendronate is actually even a little more cost-effective than our analyses have shown. 
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Half cycle correction
In the model, all fractures are assumed to happen at the end of a cycle. This is not realistic, as 
patients in real life move between different health states continuously, not at certain points in 
time. This can lead to an overestimation or underestimation of costs and quality of life, and 
half cycle correction is a way of correcting for this. Half cycle correction is not included in 
our model, and since all transitions happen at the end of the cycles, this implies that total 
costs and health benefits are underestimated but it is unlikely to affect the results of the 
incremental analyses because half cycle correction was omitted in both branches of the 
decision tree [7].
Quality of life
We assume that our population have population norm utility pre-fracture. This may not be a 
valid assumption as low BMD is highly correlated with other risk factors. Our population 
may thus suffer from more co-morbidity and have lower quality of life without fractures, 
than what we have modelled. 
We chose the highest utility values we could find for all health states in the model. These 
values are based on small a sample sizes, however. Our choice of high utility values 
associated with fractures and their sequelae will tend to make alendronate look less cost 
effective, than if we had chosen lower values. In other words; the QALY gains of the model 
are relatively modest. They do however compare well with the results reported by 
Christensen and co-workers [13]. In this study the incremental QALY gain for a woman 71-
year old woman with a z-score of -1.1 (T-score of -2.9 in their reference material) was 
0.0219 discounted QALYs. In our analysis the result in undiscounted QALYs gained for a 
70-year old woman with Z-score of -1.1 (T-score equal to -2.5 in our reference material) was 
0.0220.
We tried to run our model with the values used by Borgstrom and co-workers [5]. In order to 
do this we calculated multipliers based on the pre-fracture utilities stated in their study. 
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Table 14 Values found in Borgstrom et al. (2006)
We then assumed that that the multipliers for the fracture events were those found after four 
months and that based the multipliers for the sequelae health states on the values found after 
twelve months. Utilities associated with the different hip sequelae were calculated based on 
the same assumptions as used in the base case.
Table 15 QALY gains based on utility weights from Borgstrom et al
The QALY gains are here approximately twice those found in our base case. In our analysis, 
the choice of quality of life input does not change the conclusion; the treatment option is still 
dominant. This exercise does however illustrate an important point, namely that an economic
model like ours, with many sequelae health states, is potentially very sensitive to the choice 
of quality of life input. 
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Adverse effects of alendronate
Adverse effects of alendronate are not included in our analyses. However, if the patients 
experience adverse effects, this may imply disutility for the patients because of pain or 
discomfort, and additional costs to the society. Adverse effects could in theory be modelled, 
but data on consequences of such effects are scant. Assuming that one out hundred patients 
treated with alendronate develops dyspepsia for one month every year on treatment, and that 
this will give a utility loss of 0.014 QALY (equal to the utility loss of a forearm fracture for a 
70 year old) every year, the total utility loss for four years of treatment in our cohort of 10000 
will be 0.014*(1/12*4)/100=0.00005 QALY. We find it unlikely that such a small loss 
would have any impact on the conclusions. 
Compliance
One would imagine that side effects can cause decreased adherence to drug therapy, and thus 
the patient will have lower effect of the treatment than under optimal circumstances. In 
general, a decrease in adherence will decrease the total spending on alendronate, but may 
also increase spending related to fractures because fewer fractures are avoided. It is not clear 
what effect lower adherence will have on the cost-effectiveness ratio of alendronate. It would 
be interesting to analyze the effect of different levels of adherence, but to be able to do this 
we would need more data.
Fracture risk
The absolute fracture rates stay the same over the whole course of our model.
We have not modelled increased risk of new fractures in patients with previous fractures. 
Presumably, we will have the correct number of fractures, but that they will be distributed 
across too many individuals. The consequences of this bias are unlikely to change the 
conclusions.
Mortality
We have assumed that mortality rates will stay the same as in 2006 for the whole course of 
the model. This is very unlikely to be the case, but it is impossible to estimate how mortality 
might change, and the impact on our result is therefore uncertain.
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Excess mortality after vertebral fractures is not included. Inclusion of, and partial 
reversibility of this excess mortality like we have done for hip fractures would have made 
our result more cost effective.
Sequela after under forearm fracture
A small proportion of patients have complications after forearm fracture, but we have not 
included permanent sequalae in our model. Inclusion of such a sequela would increase the 
possible QALY gain from treatment with alendronate. The impact on our result would 
depend upon whether or not and to what degree a sequela would increase costs. The 
exclusion of this long term effect of underarm fractures is unlikely to have any significant 
impact on our result, as the proportion of patients affected is likely to be insignificant.
Exclusion of other fractures
Only hip, vertebral and forearm fractures are modelled, and other fractures are omitted from 
the model, which means that the model may underestimate the benefits of osteoporosis 
interventions.
4.2 Findings of other CE-studies
The findings of other studies give different results based on both model structure and choice 
of input. Comparisons with results from other studies are important in order to validate the 
structure of the model. It is however important to keep in mind that choice of input do have a 
large impact on the ICER. On the input side, ICERs will differ on account of factors 
associated with the population, i.e. differences in epidemiology like incidence and prevalence 
of the disease and prevalence of risk factors and co-morbidities [60]. An intervention will 
generally be more cost-effective in a country where the prevalence and incidence are high. In 
our context this will mean that prevention of osteoporosis related fractures is more likely to 
be cost effective in Scandinavia witch has a high incidence, than in the rest of Europe (see 
table ). ICERs will also differ due to factors which have an impact on the cost side; this can 
be price of drug and cost of health care services. A difference in organisation and financing 
of care does influence cost of care [60]. Finally ICERs can differ on account of 
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methodological factors, like differences in perspective, choice of discount rate, costing 
method and choice of utility input [60].
 When comparing our results with results from other studies, we have chosen to look only at 
studies conducted on Scandinavian populations. The table shown below is not a complete list 
of all studies.
Table 16; Findings of other Scandinavian CE-studies
In our study, alendronate is dominant for all nine groups, which are in line with the findings 
of Strom and co-workers [88]. In this article, incidence data for hip fractures is extrapolated 
from Oslo to the whole of Norway, which will overestimate the Norwegian incidence, as the 
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incidence in Oslo may be higher than in the rest of the country. This will make their result 
look more favourable than it really is based on the other input. The ICER is however very 
sensitive to the price of alendronate, and we have used an even lower price than this study, as 
the generic competition has reduced the price further.
Christensen and co-workers [13] do not have a dominate result in the base case, but in their 
sensitivity analysis, alendronate becomes dominant if treatment is extended from three to 
five years, if alendronate had an offset-time of three years, or if the proportion of patients 
having severe sequelae was increased or if the intervention group had a risk of fracture which 
was four times that of the background population. We have in practise fulfilled the three first 
conditions, so considering this; our findings are in line with these results. 
The main reason our result differ from the other analysis can be that we use an annual drug 
cost which is approximately one fourth of those previously used.
4.3 Policy implications
Our results indicate that treatment with alendronate is more effective and less costly than no 
treatment for women between 65, 70 and 75 with a t-score between -1.5, -2.0 and -2.5. The 
sensitivity analysis indicated that the result is robust for changes in all variables. We 
conclude that treatment of these groups fulfil the cost-effectiveness criterion in the priority 
setting guidelines. As described in the introduction, the cost effectiveness is however not the 
only criterion for priority setting. Policy makers must first consider whether or not the 
severity criterion is fulfilled and whether the effectiveness is sufficiently documented for 
these groups. It should also be noted that lower price of alendronate will tend to make other 
osteoporosis treatments less cost-effective than they were before.
Even if we assume that the three first criteria are fulfilled, there are still other things which 
need to be considered. The programme we have considered here is cost saving. The size of 
the savings will depend on the size of the target population. This means that the capacity of 
the health and social sector can be spent on other patients, instead of this patient group.
Second; ethical aspects of giving treatment to more groups of the population have to be 
considered. Decreasing BMD is a natural consequence of getting older. Low BMD is 
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asymptomatic, but results in increased fracture risk. It has been argued that treating groups at 
risk of disease represents a medicalisation. 
4.4 Conclusion
We conclude that use of alendronate with the current prices is cost-effective in a wide range 
of patients. The Norwegian guidelines for osteoporosis need to be revised to accommodate 
the changes in cost-effectiveness. 
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Appendix 1: Costs
Table 17; Unit Costs [1, 1, 12, 13, 18, 21, 66-69, 75, 76, 79, 84, 85, 89]
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Table 18; Hip fracture costs first year [100]
Table 19; vertebral fracture costs first year
Table 20; Forearm fracture costs first year
73
Table 21; Costs of moderate hip fracture sequelae and vertebral fracture sequelae
Table 22; Costs of severe hip fracture sequelae
Table 23; Treatment costs first year
Table 24; Treatment costs subsequent years
74
Appendix 2: Fracture Incidence
Table 25; Incidence of hip fractures [54]
Table 26; Incidence of vertebral fractures[46]
75
Appendix 3: Quality of Life Multipliers
Calculation of multipliers connected to events
Table 27; Calculation of multipliers for fracture events [5, 44, 94, 95]
Quality of life post-fracture is divided by quality of life pre-fracture in order in get the 
multipliers.
Calculation of multipliers for hip sequelae health states
Table 28: Values found in Tosteson et al. 2001 [95]
We used the reported quality of life for the people without any fractures as a proxy for the 
pre-fracture utility. In this study [95] the pre-fracture value was 0.91. The multiplier for 
moderate sequelae was calculated as the mean utility value after fracture divided with the 
pre-fracture utility; 0.79/0.91=0.868. We assumed that the 95% confidence intervals reported 
in the paper was based on a normal distribution. Standard error was calculated as 
0.79+1.96*SE=0.92 and 0.79-1.96*SE=0.66, which implied SE=0.0663. We assumed that 
quality of life for patients in mild sequelae would be one SE above the mean. The multiplier 
for mild hip sequelae then became (0.79+0.0663)/0.91=0.941. We followed the same 
approach for severe sequelae and found that the multiplier became (0.79-
0.0663)/0.91=0.795.
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Appendix 4: Background mortality
Table 29: Background mortality [85]
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Appendix 5: Search strategies
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